Abstract
Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through the end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) super-region. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, White race, male sex, BMI, and higher burden of cardiovascular risk.
Read the full article published in the Journal of Infectious Diseases here.
Read the plain language summary here.